Miami, Florida, August 31, 2026
RedHill Biopharma Ltd. announced that it has entered into an agreement to divest Talicia® (omeprazole, amoxicillin and rifabutin) to Apotex Inc. for $18 million in upfront cash, together with potential milestone payments. The transaction is part of RedHill’s strategy to strengthen its financial position and redirect resources toward strategic growth opportunities. Talicia is an FDA-approved oral prescription therapy indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults. The divestiture is expected to transfer commercial responsibility for the established gastrointestinal product while providing RedHill with immediate capital and the potential for additional value through future milestones.
RedHill to Receive $18 Million Upfront
Under the agreement, RedHill will receive $18 million in cash upfront from Apotex in exchange for rights to Talicia. In addition to the upfront consideration, the transaction includes potential milestone payments, giving RedHill an opportunity to receive additional proceeds based on specified future events. The structure enables the company to monetize an existing commercial pharmaceutical asset while maintaining the possibility of additional financial returns. The transaction reflects a broader portfolio management strategy in which pharmaceutical companies may divest marketed products to generate capital and concentrate resources on selected business priorities. For RedHill, the Talicia divestiture provides an immediate source of funding that the company intends to use to support its strategic growth initiatives. Talicia is a three-drug combination containing omeprazole, amoxicillin and rifabutin. The product was developed to address H. pylori infection, a bacterial infection associated with gastrointestinal disease. By combining an acid-reducing agent with two antibacterial components, Talicia provides a specific treatment regimen designed to eradicate H. pylori in eligible adult patients.
Apotex Expands Talicia Commercial Opportunity
The transaction gives Apotex an opportunity to take on the commercial rights and responsibilities associated with Talicia. Apotex is a global pharmaceutical company with a broad portfolio of generic and branded medicines, and the acquisition adds an established gastrointestinal product to its commercial operations. For Apotex, acquiring Talicia provides access to a differentiated H. pylori treatment containing rifabutin as part of a fixed-dose combination. H. pylori eradication can be challenging because treatment outcomes may be influenced by antimicrobial resistance and patient adherence. A combination product can provide a defined treatment regimen, although individual treatment decisions remain dependent on clinical circumstances and prescribing information. The divestiture does not represent the discontinuation of Talicia as a therapy. Instead, it involves a transfer of the product from RedHill to Apotex, subject to the terms and conditions of the agreement. The transaction is therefore positioned as a pharmaceutical asset transfer designed to align commercial ownership with the respective strategic priorities of both companies.
Advertisement
Transaction Supports RedHill Strategic Growth
The $18 million upfront payment provides RedHill with additional financial resources as it evaluates opportunities for future growth. Pharmaceutical asset divestitures can allow companies to unlock value from marketed products while reducing the resources required to maintain commercial operations associated with those assets. RedHill said the proceeds from the transaction will help fuel strategic growth opportunities, indicating that the company intends to focus its available capital on areas it considers strategically important. Potential milestone payments could provide further financial support if the specified conditions under the agreement are achieved. Talicia’s transfer also illustrates the continuing evolution of pharmaceutical portfolios, where companies periodically reassess marketed products based on commercial potential, strategic fit and capital requirements. For RedHill, divesting Talicia creates an opportunity to redeploy capital, while Apotex gains an established product with an existing role in the treatment of H. pylori infection. The transaction remains subject to applicable closing conditions and the terms outlined in the agreement. Following completion, Apotex will assume the relevant commercial responsibilities for Talicia. For RedHill, the deal represents a significant business-development milestone, combining immediate cash proceeds with potential future milestone value while supporting the company’s plans for strategic growth.
Source: RedHill Biopharma, Apotex press relese
